Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

PRSS3/Mesotrypsin and kallikrein-related peptidase 5 are associated with poor prognosis and contribute to tumor cell invasion and growth in lung adenocarcinoma.

Ma H, Hockla A, Mehner C, Coban M, Papo N, Radisky DC, Radisky ES.

Sci Rep. 2019 Feb 12;9(1):1844. doi: 10.1038/s41598-018-38362-0.

2.

Disulfide engineering of human Kunitz-type serine protease inhibitors enhances proteolytic stability and target affinity toward mesotrypsin.

Cohen I, Coban M, Shahar A, Sankaran B, Hockla A, Lacham S, Caulfield TR, Radisky ES, Papo N.

J Biol Chem. 2019 Mar 29;294(13):5105-5120. doi: 10.1074/jbc.RA118.007292. Epub 2019 Jan 30.

PMID:
30700553
3.

Mapping protein selectivity landscapes using multi-target selective screening and next-generation sequencing of combinatorial libraries.

Naftaly S, Cohen I, Shahar A, Hockla A, Radisky ES, Papo N.

Nat Commun. 2018 Sep 26;9(1):3935. doi: 10.1038/s41467-018-06403-x.

4.

A potent, proteolysis-resistant inhibitor of kallikrein-related peptidase 6 (KLK6) for cancer therapy, developed by combinatorial engineering.

Sananes A, Cohen I, Shahar A, Hockla A, De Vita E, Miller AK, Radisky ES, Papo N.

J Biol Chem. 2018 Aug 17;293(33):12663-12680. doi: 10.1074/jbc.RA117.000871. Epub 2018 Jun 22.

5.

Pre-equilibrium competitive library screening for tuning inhibitor association rate and specificity toward serine proteases.

Cohen I, Naftaly S, Ben-Zeev E, Hockla A, Radisky ES, Papo N.

Biochem J. 2018 Apr 16;475(7):1335-1352. doi: 10.1042/BCJ20180070.

6.

An Acrobatic Substrate Metamorphosis Reveals a Requirement for Substrate Conformational Dynamics in Trypsin Proteolysis.

Kayode O, Wang R, Pendlebury DF, Cohen I, Henin RD, Hockla A, Soares AS, Papo N, Caulfield TR, Radisky ES.

J Biol Chem. 2016 Dec 16;291(51):26304-26319. Epub 2016 Nov 3.

7.

Combinatorial protein engineering of proteolytically resistant mesotrypsin inhibitors as candidates for cancer therapy.

Cohen I, Kayode O, Hockla A, Sankaran B, Radisky DC, Radisky ES, Papo N.

Biochem J. 2016 May 15;473(10):1329-41. doi: 10.1042/BJ20151410. Epub 2016 Mar 8.

8.

Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers.

Mehner C, Oberg AL, Kalli KR, Nassar A, Hockla A, Pendlebury D, Cichon MA, Goergen KM, Maurer MJ, Goode EL, Keeney GL, Jatoi A, Sahin-Tóth M, Copland JA, Radisky DC, Radisky ES.

Oncotarget. 2015 Nov 3;6(34):35737-54. doi: 10.18632/oncotarget.5927.

9.

Mesotrypsin Has Evolved Four Unique Residues to Cleave Trypsin Inhibitors as Substrates.

Alloy AP, Kayode O, Wang R, Hockla A, Soares AS, Radisky ES.

J Biol Chem. 2015 Aug 28;290(35):21523-35. doi: 10.1074/jbc.M115.662429. Epub 2015 Jul 14.

10.

Sequence and conformational specificity in substrate recognition: several human Kunitz protease inhibitor domains are specific substrates of mesotrypsin.

Pendlebury D, Wang R, Henin RD, Hockla A, Soares AS, Madden BJ, Kazanov MD, Radisky ES.

J Biol Chem. 2014 Nov 21;289(47):32783-97. doi: 10.1074/jbc.M114.609560. Epub 2014 Oct 9.

11.
12.

PRSS3/mesotrypsin is a therapeutic target for metastatic prostate cancer.

Hockla A, Miller E, Salameh MA, Copland JA, Radisky DC, Radisky ES.

Mol Cancer Res. 2012 Dec;10(12):1555-66. doi: 10.1158/1541-7786.MCR-12-0314.

13.

PEGylation extends circulation half-life while preserving in vitro and in vivo activity of tissue inhibitor of metalloproteinases-1 (TIMP-1).

Batra J, Robinson J, Mehner C, Hockla A, Miller E, Radisky DC, Radisky ES.

PLoS One. 2012;7(11):e50028. doi: 10.1371/journal.pone.0050028. Epub 2012 Nov 20.

14.

The P(2)' residue is a key determinant of mesotrypsin specificity: engineering a high-affinity inhibitor with anticancer activity.

Salameh MA, Soares AS, Hockla A, Radisky DC, Radisky ES.

Biochem J. 2011 Nov 15;440(1):95-105. doi: 10.1042/BJ20110788.

15.

Mesotrypsin promotes malignant growth of breast cancer cells through shedding of CD109.

Hockla A, Radisky DC, Radisky ES.

Breast Cancer Res Treat. 2010 Nov;124(1):27-38. doi: 10.1007/s10549-009-0699-0. Epub 2009 Dec 25.

16.

Structural basis for accelerated cleavage of bovine pancreatic trypsin inhibitor (BPTI) by human mesotrypsin.

Salameh MA, Soares AS, Hockla A, Radisky ES.

J Biol Chem. 2008 Feb 15;283(7):4115-23. Epub 2007 Dec 12.

Supplemental Content

Loading ...
Support Center